全文获取类型
收费全文 | 1082篇 |
免费 | 57篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 20篇 |
妇产科学 | 10篇 |
基础医学 | 110篇 |
口腔科学 | 44篇 |
临床医学 | 70篇 |
内科学 | 232篇 |
皮肤病学 | 25篇 |
神经病学 | 67篇 |
特种医学 | 269篇 |
外科学 | 72篇 |
综合类 | 4篇 |
预防医学 | 99篇 |
眼科学 | 14篇 |
药学 | 64篇 |
肿瘤学 | 37篇 |
出版年
2023年 | 6篇 |
2022年 | 17篇 |
2021年 | 22篇 |
2020年 | 23篇 |
2019年 | 33篇 |
2018年 | 22篇 |
2017年 | 22篇 |
2016年 | 19篇 |
2015年 | 19篇 |
2014年 | 38篇 |
2013年 | 47篇 |
2012年 | 69篇 |
2011年 | 64篇 |
2010年 | 26篇 |
2009年 | 31篇 |
2008年 | 49篇 |
2007年 | 55篇 |
2006年 | 39篇 |
2005年 | 27篇 |
2004年 | 31篇 |
2003年 | 27篇 |
2002年 | 27篇 |
2001年 | 15篇 |
2000年 | 9篇 |
1999年 | 16篇 |
1998年 | 24篇 |
1997年 | 22篇 |
1996年 | 16篇 |
1995年 | 16篇 |
1994年 | 22篇 |
1993年 | 17篇 |
1992年 | 6篇 |
1991年 | 5篇 |
1990年 | 10篇 |
1989年 | 28篇 |
1988年 | 24篇 |
1987年 | 29篇 |
1986年 | 19篇 |
1985年 | 19篇 |
1984年 | 23篇 |
1983年 | 15篇 |
1982年 | 13篇 |
1981年 | 19篇 |
1980年 | 15篇 |
1978年 | 11篇 |
1977年 | 6篇 |
1976年 | 8篇 |
1975年 | 4篇 |
1974年 | 3篇 |
1968年 | 3篇 |
排序方式: 共有1145条查询结果,搜索用时 15 毫秒
1.
Carlos Cotrim Otília Sim?es M J Loureiro Pedro Cordeiro Rita Miranda Cecília Silva Teresa Avillez Manuel Carrageta 《Revista portuguesa de cardiologia》2006,25(5):529-533
We describe the case of a pregnant woman with idiopathic pulmonary arterial hypertension, a responder in right heart catheterization, followed since the first trimester in outpatient consultations, admitted to hospital at 23 weeks gestation. She was treated with inhaled iloprost until delivery (at 34 weeks gestation) and continuous infusion of iloprost throughout the perioperative period and following days. This line of therapy has proved efficacious in previous cases. The authors present echocardiographic images that document acute changes in ventricular synchrony during inhalation of iloprost. 相似文献
2.
3.
4.
Normal and diseased isolated lungs: high-resolution CT 总被引:8,自引:0,他引:8
5.
6.
Pedro Magno José Loureiro Alexandre Marques Pedro Farto E Abreu Machado Candido Paulo Leal Victor M Gil 《Revista portuguesa de cardiologia》2007,26(10):1033-1042
Ischemic stroke occurs in 0.2-0.4% of patients undergoing left heart catheterization, and is responsible for 5-10% of the mortality associated with the procedure. The main predisposing factors for this complication are female gender, complex atherosclerotic plaques in the ascending aorta, and peripheral arterial disease. The possibility of timely intervention with reperfusion therapy supports close clinical monitoring during the immediate post-catheterization period. The cardiologist should be familiar with the various types of stroke reperfusion therapy and its indications according to the time interval between catheterization and the stroke. The decision should be discussed with neurology and neuroradiology. 相似文献
7.
P N Palma M J Bonifácio A I Loureiro L C Wright D A Learmonth P Soares-da-Silva 《Drug metabolism and disposition》2003,31(3):250-258
Catechol-O-methyltransferase (COMT, EC 2.1.1.6) plays a central role in the metabolic inactivation of neurotransmitters and neuroactive xenobiotics possessing a catechol motif. 1-(3,4-Dihydroxy-5-nitrophenyl)-2-phenyl-ethanone (BIA 3-202) is a novel nitrocatechol-type inhibitor of COMT, the potential clinical benefit of which is currently being evaluated in the treatment of Parkinson's disease. In the present work we characterize the molecular interactions of BIA 3-202 within the active site of COMT and discuss their implication on the regioselectivity of metabolic O-methylation. Unrestrained flexible-docking simulations suggest that the solution structure of this complex is better described as an ensemble of alternative binding modes, in contrast to the well defined bound configuration revealed by the X-ray structures of related nitrocatechol inhibitors, co-crystallized with COMT. The docking results wherein presented are well supported by experimental evidence, where the pattern of in vitro enzymatic O-methylation and O-demethylation reactions are analyzed. We propose a plausible explanation for the paradoxical in vivo regioselectivity of O-methylation of BIA 3-202, as well as of its related COMT inhibitor tolcapone. Both compounds undergo in vivo O-methylation by COMT at either meta or para catechol hydroxyl groups. However, results herein presented suggest that, in a subsequent step, the p-O-methyl derivatives are selectively demethylated by a microsomal enzyme system. The overall balance is the accumulation of the m-O-methylated metabolites over the para-regioisomers. The implications for the general recognition of nitrocatechol-type inhibitors by COMT and the regioselectivity of their metabolic O-methylation are discussed. 相似文献
8.
Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. 总被引:1,自引:0,他引:1
Collins CE Benson MJ Burnham WR Rampton DS 《Alimentary pharmacology & therapeutics》1996,10(3):315-320
BACKGROUND: Inflammatory bowel disease is associated with increased mucosal release of eicosanoids. Among these, thromboxane A2 has been proposed as a possible inflammatory mediator; its suppression may be a useful therapeutic option. METHODS: Using a tissue incubation technique, we compared release of immunoreactive thromboxane B2 by colonic biopsies from patients with ulcerative colitis, Crohn's disease and controls, and assessed the inhibitory effect of picotamide, a thromboxane synthesis inhibitor-receptor antagonist, which has been widely used in Italy for management of ischaemic heart and cerebrovascular disease. RESULTS: Increased amounts of thromboxane B2 were released from biopsies from patients with active ulcerative colitis (median 238 pg/20 min/mg wet weight (interquartile range 147- 325), n = 12) and active Crohn's disease (252 (174-450), 6) compared with those from patients with quiescent ulcerative colitis (95 (61- 140), 12) or Crohn's disease (105 (57-201), 13), or controls (136 (64- 206), 8). Incubation with picotamide at concentrations between 100 microM and 1 mM reduced thromboxane B2 release (IC50 890 microM). CONCLUSION: Since increased thromboxane A2 production may have pathogenetic importance, thromboxane synthesis inhibitor-receptor antagonists such as picotamide merit therapeutic trial in the management of inflammatory bowel disease. 相似文献
9.
10.